Germline TP53 mutations undergo copy number gain years prior to tumor diagnosisNicholas Light, Adam Shlien, Anita Villani et al.|Nature Communications|2023Cited by 46
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i> -Mutated Advanced Urothelial CarcinomaSumati Gupta, Sunil Sharma, Alexis Weston et al.|Molecular Cancer Therapeutics|2018Cited by 24
Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC).Sumati Gupta, Neeraj Agarwal, Daniel J. Albertson et al.|Journal of Clinical Oncology|2017Cited by 2
Supplemental figure 4 from Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i>-Mutated Advanced Urothelial CarcinomaSumati Gupta, Sunil Sharma, Alexis Weston et al.|Unknown|2023Cited by 0